SLC5A2 and chronic kidney disease: Dual SGLT-1 and SGLT-2 inhibitors might produce more pronounced weight loss [115], and were recently approved to reduce the risk of cardiovascular death or worsening of heart failure in people with pre-existing heart failure or with T2D, CKD, and cardiovascular risk factors [95].